Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma
Shots:
- The US FDA has accepted the BLA for toripalimab + CT (gemcitabine & cisplatin) & toripalimab as monothx. to treat advanced recurrent or metastatic NPC after platinum-containing CT. The US FDA has granted PR designation of toripalimab BLA with an anticipated PDUFA date on Apr'22
- The BLA is based on the P-II POLARIS-02 & P-III JUPITER-02 study. In 2021, Coherus got the licensed rights to develop and commercialize toripalimab in the US and Canada
- In Aug'21, toripalimab + CT has received the BTD for recurrent, LA, or primary metastatic non-keratinizing NPC. Additionally, both companies plan to file additional toripalimab's BLA with the US FDA over the next 3yrs. for multiple cancer article
Ref: Globe Newswire | Image: Coherus
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com